RETN and breast cancer: When we analyzed the relationship between resistin and EGFR expression in breast cancer tissue specimens, we found significantly higher levels of positive or strongly positive EGFR expression among resistin-positive cases (57.7% [188/326] and 35.9% [117/326], respectively) compared with resistin-negative cases (24.2% [16/66] (P < 0.001) and 15.2% [10/66] (P = 0.001), respectively, Table 3).